Hans M.
- Country
- The Netherlands
- Department
- Solid Tumours
Research Overview
- Evaluation of Irinotecan, Ifosfamide, Vincristine, and Dactinomycin in Frontline and Relapsed Rhabdomyosarcoma in Pediatric and Adult Populations
- Randomized Controlled Trial of Chemotherapy Regimens Including Gemcitabine, Lenvatinib, and Temozolomide for Recurrent and Primary Refractory Ewing Sarcoma
Data & Insights
Has run more than one trial at 33 of 178 partner sites.
Specializations
Sarcoma Research
The investigator specializes in treating rare and aggressive forms of sarcoma, with particular emphasis on rhabdomyosarcoma and Ewing sarcoma. Their research encompasses both frontline treatments and therapeutic approaches for relapsed cases.
- Primary Rhabdomyosarcoma Management
- Refractory Ewing Sarcoma Treatment
- Recurrent Sarcoma Therapies
Their work includes evaluating novel combination therapies and treatment intensification strategies for high-risk patients.
Therapeutic Innovation
This clinical researcher focuses on developing and assessing innovative therapeutic combinations, including multimodal treatment approaches that incorporate chemotherapy and radiotherapy. Their work involves investigating novel drug combinations and treatment schedules.
- Combination Chemotherapy Protocols
- Maintenance Therapy Optimization
- Risk-Adapted Treatment Strategies
Their research explores treatment intensification and duration modifications based on patient risk categories.
Radiation Oncology
The investigator studies optimal timing and dosing of radiotherapy interventions, particularly in the context of sarcoma treatment. Their research examines both pre-operative and post-operative radiation approaches.
- Radiation Timing Optimization
- Dose Escalation Studies
- Metastatic Site Treatment
Their work includes evaluating radiation strategies for both localized and metastatic disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.